ClinicalTrials.gg
Sign In

Drug

BTK Inhibitor TQB3702 clinical trials

studies test it
4
open now
3
in phase 3
0
first study started
2022

Keep track of what changes. Save the BTK Inhibitor TQB3702 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

TQB3702 tablets
4

Studies by the year they started

4 studies that test it; most in 2024 (2)

Studies that test BTK Inhibitor TQB3702, by start year
YearStudies
20221
20242
20251

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it.

Lupus Erythematosus, Systemic
2
Hematologic Neoplasms
2

Who runs them

Industry 4 · Other 0

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (4)

Often tested with

Tested in the same studies.

Bcl-2 Inhibitor TQB3909 (1)

Studies

Open first, then newest update. How each study uses BTK Inhibitor TQB3702 is read from its arms, and is right about nine times in ten.

Testing it · 4